Fundraising Fox

Relmada Therapeutics

NASDAQ: RLMD

New York, US · Founded 2012 · Nevada corporation · 1 known investors

Biotech

Founders & leadership

ST
Sergio TraversaExecutive
EO
Eliseo O. SalinasPresident and Chief Scientific Officer
DB
Douglas BeckChief Financial Officer
CC
Charles CasamentoNamed on SEC filing
PK
Paul KellyNamed on SEC filing
MS
Maged ShenoudaNamed on SEC filing

Board

SS
Sandesh SethLead Director
SA
Shreeram AgharkarBoard director
NM
Nabil M. YazgiBoard director

Investors · 1

BioAdvanceConshohocken · $500K – $1.5M

Reported raises · per SEC filings

Form D private placements

$51.1M disclosed across 7 of 8 rounds · 2014–2019

▶$825.8KraisedOct 2019 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Maged ShenoudaDirector
  • Ottavio VitoloExecutive Officer
  • Paul KellyDirector
  • Charles CasamentoDirector
  • Chuck EnceExecutive Officer
  • Sergio TraversaExecutive Officer, Director
Offering amount
$825.8K
Amount sold
$825.8K
Minimum investment
$10K
First sale
Sep 2019
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.4MraisedJul 2019 · 116 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles CasamentoDirector
  • Sergio TraversaExecutive Officer, Director
  • Ottavio VitoloExecutive Officer
  • Paul KellyDirector
  • Maged ShenoudaDirector
Offering amount
$10M
Amount sold
$8.4M
Minimum investment
$10K
Sales commissions
$688.9K
Placement agents
Brookline Capital Markets, A division of Arcadia Securities, LLC, Alexander Capital, LP
First sale
Jun 2019
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.4MraisedMay 2019 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sergio TraversaExecutive Officer, Director
  • Charles CasamentoDirector
  • Ottavio VitoloExecutive Officer
  • Maged ShenoudaDirector
  • Paul KellyDirector
Offering amount
$10M
Amount sold
$3.4M
Minimum investment
$10K
Sales commissions
$221.2K
Placement agents
Alexander Capital, LP, Brookline Capital Markets, A division of CIM Securities, LLC
First sale
May 2019
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.8MraisedDec 2018 · 66 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul KellyDirector
  • Ottavio VitoloExecutive Officer
  • Sergio TraversaExecutive Officer, Director
  • Maged ShenoudaDirector
  • Charles CasamentoDirector
Offering amount
$10M
Amount sold
$5.8M
Minimum investment
$10K
Sales commissions
$563.9K
Placement agents
Alexander Capital, LP
First sale
Oct 2018
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.9MraisedOct 2017 · 65 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sergio TraversaExecutive Officer, Director
  • Charles CasamentoDirector
  • Paul KellyDirector
  • Maged ShenoudaDirector
Offering amount
$6.9M
Amount sold
$6.9M
Minimum investment
$5K
Sales commissions
$584.5K
Placement agents
Alexander Capital, LP
First sale
Sep 2017
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.7MraisedJun 2014 · 236 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nabil M. YazgiDirector
  • Douglas BeckExecutive Officer
  • Sergio TraversaExecutive Officer, Director
  • Shreeram AgharkarDirector
  • Sandesh SethDirector
  • Eliseo O. SalinasExecutive Officer
Offering amount
$10.7M
Amount sold
$10.7M
Minimum investment
$100K
Sales commissions
$1.1M
Placement agents
Laidlaw & Company (UK) Ltd.
First sale
Jun 2014
Incorporated
Corporation, Nevada, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedJun 2014 · 382 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas BeckExecutive Officer
  • Sergio TraversaExecutive Officer, Director
  • Sandesh SethDirector
  • Eliseo O. SalinasExecutive Officer
  • Nabil M. YazgiDirector
  • Shreeram AgharkarDirector
First sale
May 2014
Incorporated
Corporation, Nevada, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.1MraisedMay 2014 · 225 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Eliseo O. SalinasExecutive Officer
  • Douglas BeckExecutive Officer
  • Sandesh SethDirector
  • Shreeram AgharkarDirector
  • Nabil M. YazgiDirector
  • Sergio TraversaExecutive Officer, Director
Offering amount
$15.1M
Amount sold
$15.1M
Minimum investment
$100K
Sales commissions
$1.8M
Placement agents
Laidlaw & Company (UK) Ltd.
First sale
May 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Relmada Therapeutics's investors?
Relmada Therapeutics's investors include BioAdvance.
How much funding has Relmada Therapeutics raised?
Relmada Therapeutics has disclosed $51.1M raised across 7 of its 8 known rounds.
Where is Relmada Therapeutics headquartered?
Relmada Therapeutics is headquartered in New York, US.